155 related articles for article (PubMed ID: 38035973)
1. Hypothetical biosynthetic pathways of pharmaceutically potential hallucinogenic metabolites in Myristicaceae, mechanistic convergence and co-evolutionary trends in plants and humans.
Barman R; Kumar Bora P; Saikia J; Konwar P; Sarkar A; Kemprai P; Proteem Saikia S; Haldar S; Slater A; Banik D
Phytochemistry; 2024 Feb; 218():113928. PubMed ID: 38035973
[TBL] [Abstract][Full Text] [Related]
2. "In vivo biosynthesis of N,N-dimethyltryptamine, 5-MeO-N,N-dimethyltryptamine, and bufotenine in E.coli".
Friedberg LM; Sen AK; Nguyen Q; Tonucci GP; Hellwarth EB; Gibbons WJ; Jones JA
Metab Eng; 2023 Jul; 78():61-71. PubMed ID: 37230161
[TBL] [Abstract][Full Text] [Related]
3. Monoamine oxidase inhibitors in South American hallucinogenic plants Part 2: Constituents of orally-active Myristicaceous hallucinogens.
McKenna DJ; Towers GH; Abbott FS
J Ethnopharmacol; 1984 Nov; 12(2):179-211. PubMed ID: 6521493
[TBL] [Abstract][Full Text] [Related]
4. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and beta-carboline constituents of ayahuasca.
McKenna DJ; Towers GH; Abbott F
J Ethnopharmacol; 1984 Apr; 10(2):195-223. PubMed ID: 6587171
[TBL] [Abstract][Full Text] [Related]
5. The hallucinogenic world of tryptamines: an updated review.
Araújo AM; Carvalho F; Bastos Mde L; Guedes de Pinho P; Carvalho M
Arch Toxicol; 2015 Aug; 89(8):1151-73. PubMed ID: 25877327
[TBL] [Abstract][Full Text] [Related]
6. Indolethylamine N-methyltransferase (INMT) is not essential for endogenous tryptamine-dependent methylation activity in rats.
Glynos NG; Carter L; Lee SJ; Kim Y; Kennedy RT; Mashour GA; Wang MM; Borjigin J
Sci Rep; 2023 Jan; 13(1):280. PubMed ID: 36609666
[TBL] [Abstract][Full Text] [Related]
7. The role of 5-HT2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice.
Carbonaro TM; Eshleman AJ; Forster MJ; Cheng K; Rice KC; Gatch MB
Psychopharmacology (Berl); 2015 Jan; 232(1):275-84. PubMed ID: 24985890
[TBL] [Abstract][Full Text] [Related]
8. A mechanistic insight for the biosynthesis of N,N-dimethyltryptamine: An ONIOM theoretical approach.
Coutinho LP; Silva SRB; de Lima-Neto P; Monteiro NKV
Biochem Biophys Res Commun; 2023 Oct; 678():148-157. PubMed ID: 37640000
[TBL] [Abstract][Full Text] [Related]
9. Ontogeny of N,N-dimethyltryptamine and related indolealkylamine levels in neonatal rats.
Beaton JM; Morris PE
Mech Ageing Dev; 1984 Jun; 25(3):343-7. PubMed ID: 6588281
[TBL] [Abstract][Full Text] [Related]
10. In vivo long-term kinetics of radiolabeled n,n-dimethyltryptamine and tryptamine.
Vitale AA; Pomilio AB; Cañellas CO; Vitale MG; Putz EM; Ciprian-Ollivier J
J Nucl Med; 2011 Jun; 52(6):970-7. PubMed ID: 21622895
[TBL] [Abstract][Full Text] [Related]
11. Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter.
Cozzi NV; Gopalakrishnan A; Anderson LL; Feih JT; Shulgin AT; Daley PF; Ruoho AE
J Neural Transm (Vienna); 2009 Dec; 116(12):1591-9. PubMed ID: 19756361
[TBL] [Abstract][Full Text] [Related]
12. Qualitative and Quantitative Analysis of Tryptamines in the Poison of Incilius alvarius (Amphibia: Bufonidae).
Schwelm HM; Zimmermann N; Scholl T; Penner J; Autret A; Auwärter V; Neukamm MA
J Anal Toxicol; 2022 May; 46(5):540-548. PubMed ID: 33851996
[TBL] [Abstract][Full Text] [Related]
13. Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine.
Jacob MS; Presti DE
Med Hypotheses; 2005; 64(5):930-7. PubMed ID: 15780487
[TBL] [Abstract][Full Text] [Related]
14. The indole hallucinogens, N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), have different effects from mescaline on rat shuttlebox avoidance.
Stoff DM; Gorelick DA; Bozewicz T; Bridger WH; Gillin JC; Wyatt RJ
Neuropharmacology; 1978 Dec; 17(12):1035-40. PubMed ID: 284199
[No Abstract] [Full Text] [Related]
15. A narrative synthesis of research with 5-MeO-DMT.
Ermakova AO; Dunbar F; Rucker J; Johnson MW
J Psychopharmacol; 2022 Mar; 36(3):273-294. PubMed ID: 34666554
[TBL] [Abstract][Full Text] [Related]
16. Abuse liability profile of three substituted tryptamines.
Gatch MB; Forster MJ; Janowsky A; Eshleman AJ
J Pharmacol Exp Ther; 2011 Jul; 338(1):280-9. PubMed ID: 21474568
[TBL] [Abstract][Full Text] [Related]
17. Interaction of psychedelic tryptamine derivatives with a lipid bilayer.
Zohairi F; Khandelia H; Hakami Zanjani AA
Chem Phys Lipids; 2023 Mar; 251():105279. PubMed ID: 36627076
[TBL] [Abstract][Full Text] [Related]
18. Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.
Halberstadt AL
Pharmacol Biochem Behav; 2016 Apr; 143():1-10. PubMed ID: 26780349
[TBL] [Abstract][Full Text] [Related]
19. Evidence for and against the involvement of N,N-dimethyl-tryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in schizophrenia.
Gillin JC; Wyatt RJ
Psychopharmacol Bull; 1976 Oct; 12(4):12-3. PubMed ID: 1067623
[No Abstract] [Full Text] [Related]
20. Characterization of tryptamine 5-hydroxylase and serotonin synthesis in rice plants.
Kang S; Kang K; Lee K; Back K
Plant Cell Rep; 2007 Nov; 26(11):2009-15. PubMed ID: 17639402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
